Skip to content

Not medical advice. Talk to your provider before using any peptide. Full disclaimer

Peptide Schedule Research TeamReviewed Apr 7, 20268 Citations

Dulaglutide (Trulicity) peptide icon, one bubble per amino acidDulaglutide (Trulicity)31 residuesHGEGTFTSDVSSYLEEQAAKEFIAWLVKGGGEach bubble = one amino acid. Size = residue mass. Color = chemical class.

Dulaglutide (Trulicity) Dosage Calculator

Weight Loss · FDA Approved · Grade A · ~5 days half-life · Injection

Dosing protocol

Dulaglutide (Trulicity) Dosage

LevelDose / InjectionFrequency
Beginner0.75 mgWeekly
Moderate1.5 mgWeekly
Aggressive4.5 mgWeekly

Cycle: No scheduled off period.

No syringe calculation for this route

Subcutaneous

Dulaglutide (Trulicity) has no default water volume for this calculator, so there are no syringe units to calculate here. Dosing runs 0.75 mg to 4.5 mg per administration, weekly.

If your product does arrive as a powder, use the universal reconstitution calculator and enter your own vial size and water volume.

Open Dulaglutide (Trulicity) details
Side effects, protocols by goal, storage, and the sources behind these dosing numbers.

About Dulaglutide (Trulicity)

Beginner, moderate, and aggressive dosing amounts with timing. Free to use.

Dulaglutide (Trulicity) is a once-weekly GLP-1 receptor agonist with FDA approval for type 2 diabetes and cardiovascular risk reduction. The REWIND trial confirmed a 12% drop in major cardiovascular events over 5.4 years in 9,901 participants. Pre-filled pen, no mixing, no needle. Weight loss is modest compared to newer options.

GLP-1 AgonistType 2 DiabetesCardiovascularWeight ManagementFDA-Approved
Subcutaneous. Typical beginner frequency: weekly.
Store at 2-8°C (36-46°F); up to 30°C (86°F) for 14 days. Refrigerate at 2-8°C in original carton. May store at room temperature (up to 30°C) for up to 14 days.

View side effects and safety warnings →

Quick-Start: How to Use Dulaglutide (Trulicity)

  1. 1Remove one Trulicity pen from the refrigerator. Let it sit at room temperature for about 30 minutes. Cold pens sting more and are harder to activate.
  2. 2Inspect the pen window. The solution should be clear and colorless. Do not use if cloudy, discolored, or if particles are floating in it.
  3. 3Choose your injection site: abdomen, thigh, or upper arm. Rotate to a different area each week. Clean the site with an alcohol swab and let it dry.
Full usage guide →

Dulaglutide (Trulicity) Dosing Protocol

FDA LabelTrulicity (dulaglutide) FDA Prescribing Information (2022) (n=3,623 (AWARD-11))
LevelDose / InjectionFrequency
Beginner0.75 mgWeekly
Moderate1.5 mgWeekly
Aggressive4.5 mgWeekly
Note:

Trulicity ships ready to inject. No vials, no bacteriostatic water, no syringe math. Each pen contains a single fixed dose with an integrated needle. Store pens in the fridge at 2 to 8 degrees Celsius. If you need to travel, they're stable at room temperature (up to 30 degrees Celsius) for 14 days. Don't freeze them.

Before injection, let a cold pen sit out for about 30 minutes. Cold pens are the number one cause of activation failures and injection site stinging. Look through the pen window to confirm the solution is clear and colorless. Cloudy or discolored liquid means toss it.

Four dose strengths exist: 0.75 mg, 1.5 mg, 3.0 mg, and 4.5 mg. Each pen is a single strength with no volume to measure or calculate.

Start at 0.75 mg weekly. If blood sugar targets aren't met after four weeks, step up to 1.5 mg. Most community users stay at 1.5 mg long-term; that's the sweet spot between efficacy and GI tolerability for the majority. Don't rush dose escalation. GI side effects spike with every step up, and giving your gut 4 weeks to adapt makes the difference between tolerating the drug and quitting it.

Dosing based on Trulicity (dulaglutide) FDA Prescribing Information (2022): 8 published references.View all sources →

Ask AI about this math

Cross-check your Dulaglutide (Trulicity) reconstitution math with AI

Dulaglutide (Trulicity) Cost

Brand Price
~$987/month retail (4-pen, 28-day supply; all dose strengths same price without insurance). Lilly savings card: $25/month for commercially insured patients (max $150/fill, annual cap $1,950; not valid for Medicare/Medicaid/TRICARE). Most Favored Nation pricing agreement (Nov 2025): $389/month: implementation variable.
Generic / Research
No generic available. Patent protection expected until ~2031; biosimilar potential entry ~2033–2034. Some reports suggest a generic could emerge as early as 2027: unconfirmed.
Compounded
Not available. Dulaglutide is not on the FDA drug shortage list and is patent-protected as a large-molecule biologic. No legitimate compounded dulaglutide formulation exists.

Pricing updated 2026-04-09

Prices are estimates and vary by source, location, and prescription status.Full pricing breakdown →

Dulaglutide (Trulicity) Pharmacokinetics

Pharmacokinetics: Active Dose Over Time

t½ = ~5 days (120 hours)
50%25%12.5%100%75%50%25%0%05d10d15d20d25dTime after injectionDose remaining
After 1 half-life (5d): 50% remainsAfter 2 half-lives (10d): 25% remainsAfter 3 half-lives (15d): 12.5% remains
At a 1.5 mg dose: 50% = 0.75 mg remaining after 5d. Moderate-tier frequency in our sources: Weekly.

Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.

Read the full Dulaglutide (Trulicity) guide →

Related Tools

Frequently Asked Questions

Store Dulaglutide (Trulicity) at 2-8°C (36-46°F); up to 30°C (86°F) for 14 days. Refrigerate at 2-8°C in original carton. May store at room temperature (up to 30°C) for up to 14 days.

Start at 0.75 mg subcutaneous once weekly. After 4 weeks, increase to 1.5 mg weekly if tolerated. Maximum dose: 4.5 mg weekly. The 4.5 mg dose showed additional A1c and weight benefit in the AWARD-11 trial but with higher GI side effect rates.